BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30419021)

  • 1. Novel protein signatures suggest progression to muscular invasiveness in bladder cancer.
    Berle M; Ghila L; Vethe H; Chaudhry A; Garberg H; Beisland C; Haaland ØA; Oveland E; Halvorsen OJ; Davidsson T; Chera S
    PLoS One; 2018; 13(11):e0206475. PubMed ID: 30419021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.
    Silvers CR; Liu YR; Wu CH; Miyamoto H; Messing EM; Lee YF
    Oncotarget; 2016 Apr; 7(17):23335-45. PubMed ID: 26981774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
    Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression.
    Park S; Rong L; Owczarek TB; Bernardo MD; Shoulson RL; Chua CW; Kim JY; Lankarani A; Chakrapani P; Syed T; McKiernan JM; Solit DB; Shen MM; Al-Ahmadie HA; Abate-Shen C
    Cancer Res; 2021 Oct; 81(20):5161-5175. PubMed ID: 34470779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression.
    Mitrakas L; Gravas S; Papandreou C; Koukoulis G; Karasavvidou F; Dimakopoulos G; Weingärtner K; Karatzas A; Zachos I; Tzortzis V
    Pathol Oncol Res; 2019 Jan; 25(1):225-231. PubMed ID: 29081034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.
    Roudnicky F; Dieterich LC; Poyet C; Buser L; Wild P; Tang D; Camenzind P; Ho CH; Otto VI; Detmar M
    J Pathol; 2017 Jun; 242(2):193-205. PubMed ID: 28295307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
    Fristrup N; Birkenkamp-Demtröder K; Reinert T; Sanchez-Carbayo M; Segersten U; Malmström PU; Palou J; Alvarez-Múgica M; Pan CC; Ulhøi BP; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2013 Feb; 182(2):339-49. PubMed ID: 23201130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer.
    Kusuhara Y; Daizumoto K; Kawai K; Hirayama K; Kowada M; Shintani T; Fukuhara Y; Dondoo TO; Ozaki K; Tsuda M; Fukawa T; Nakatsuji H; Bando Y; Uehara H; Fukumori T; Takahashi M; Kanayama HO
    Anticancer Res; 2019 Feb; 39(2):703-711. PubMed ID: 30711948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
    Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
    Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
    Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
    Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
    Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Kim S; Lee AJ; Yeo MK; Na YG; Kim JY; Cho MJ; Kim JS; Jo EK; Kim JM
    Anticancer Res; 2018 Apr; 38(4):2429-2437. PubMed ID: 29599373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
    Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
    Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and clinical significance of Bmi-1 protein in bladder cancer].
    Qin ZK; Yang JA; Zeng MS; Zhou FJ; Han H; Liu ZW; Yu SL; Li YH; Chen ZF
    Ai Zheng; 2008 Dec; 27(12):1327-30. PubMed ID: 19080003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression.
    Jung M; Jang I; Kim K; Moon KC
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
    Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
    Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.
    Jungels C; Martinez Chanza N; Albisinni S; Mercier M; d'Haene N; Rorive S; Roumeguère T
    Prog Urol; 2018 May; 28(6):344-350. PubMed ID: 29673906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
    Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.